Guelph, ON—Nutrasource Pharmaceutical and Nutraceutical Services is now an official Institution-Wide Cannabis Research License holder under the Cannabis Act in Canada, according to a press release.
The company has obtained approval from Health Canada’s Controlled Substances and Cannabis branch, allowing Nutrasource’s clients an accelerated path to cannabis human research authorizations. The press release notes that this process otherwise involves “uncertain and prolonged timelines when submitting individual projects on a stand-alone basis,” delays which increased costs for product development, product innovation, and claims substantiation.
The license allows Nutrasource to:
- Expedite government approvals that will allow human research to be conducted at the Nutrasource site, without applying for multiple license each time a study is conducted
- Run multiple research projects at the same site for various clients simultaneously
- Conduct clinical, sensory, pharmacokinetic, pharmacodynamic, and palatability studies that would include participants.
More on Nutrasource’s offerings for cannabis and CBD can be found here.
“This license is pivotal for our client base given that regulatory approval delays in this product category have been unpredictable, which adds substantially to the client’s project timelines and cost,” said William Rowe, President and CEO of Nutrasource, in the press release.
Joshua Baisley, VP of Clinical Trial Design & Delivery, added: “As leaders in providing clinical trial services to the global cannabis industry, this institution-wide license adds additional benefit to the favorable Canadian regulatory environment, including (CTA) Clinical Trial Applications for human studies in this expansive product category. We are proud to be the first privately held and independent CRO that has been granted this type of license for human research from Health Canada.”